Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: A case study of Osimertinib versus pemetrexed-platinum

The partitioned survival model (PSM) and the state transition model (STM) are widely used in costeffectiveness analyses of anticancer drugs. Using different modeling approaches with or without consideration of brain metastasis, we compared the quality-adjusted life-year (QALY) estimates of Osimertinib and pemetrexedplatinum in advanced non-small cell lung cancer with epidermal growth factor receptor mutations.